CTOs on the Move

Prescos

www.prescos.com

 
Prescos is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.prescos.com
  • 3550 General Atomics Ct
    San Diego, CA USA 92121
  • Phone: 858.452.2001

Executives

Name Title Contact Details

Similar Companies

Molecular Designs

Better products. Better service. MOLECULAR DESIGNS Molecular Designs is a team of doctors and scientists working to advance molecular diagnostics. We do this by developing, producing, and supplying multiplex assays for molecular testing ...

Surface Logix

Surface Logix, Inc. is a Brighton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PNP Therapeutics

PNP Therapeutics is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cambrian Innovation

Spun out of MIT in 2006, Cambrian Innovation is commercializing a portfolio of environmental solutions based on newly discovered electrically active microbes. By harnessing the power of bio-electricity and advances in electrochemistry, Cambrian Innovation`s products help industrial, agricultural, and government customers save money while recovering clean water and clean energy from wastewater streams. Our bio-electrogenic sensor platform enables low-cost, real-time monitoring of critical natural resources. At Cambrian Innovation our vision is simple: Industry is an ecosystem. Because the biological world is by definition sustainable, creative application of biological engineering is the best way to solve our most pressing environmental challenges. Cambrian Innovation`s solutions leverage advances in bio-electricity to help industrial and agricultural customers cut costs while meeting their environmental goals.

TCR2

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.